Bioherent, founded in 2021 as a University of Málaga spin-off, develops miniaturized integrated photonic sensors combined with surface chemistry and advanced nanomaterials to create label-free biosensors for clinical diagnostics. Its core product is the AllerWAVE system, a compact desktop analyzer with disposable cartridges designed for rapid detection of allergies to antibiotics and acute drug reactions used in anesthesia and biological therapies. The company's technology aims to deliver faster, simplified and highly precise analyses without sending samples to external labs, reducing reliance on highly specialized personnel. Bioherent is supported by three university research groups in photonics, chemistry and medicine and has positioned AllerWAVE to address misdiagnoses of antibiotic allergies and associated antimicrobial resistance issues. In July 2025 it raised €2 million in a financing round involving Axon Partners, the CDTI (Innvierte) and Bullnet Capital, and in March it secured an additional €284,000 in a CDTI-led coinvestment to further develop its diagnostic systems.

Total raised

$0M

Funding rounds

1

Latest round

Equity

Latest activity

May 2026